| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
Pulmonary cachexia is a frequent complication in patients with respiratory failure, such as lung cancer or COPD. The key features of cachexia are reductions in body weight and skeletal muscle mass. The development of therapeutic strategies for cachectic conditions are needed in patients with these respiratory diseases.
Compared with the control mice, the pulmonary cachexia model mice had higher expression level of UCP1 in white adipose tissue, lower expression level of ghrelin in plasma and stomach, and lower activity of AgRP/NPY signaling in hypothalamus. In addition, treatment with ghrelin did not affect cell viability or proliferation in human lung adenocarcinoma cell line.
|
